Skip to Content

Ansell Ltd ANN

Rating as of

Morningstar’s Analysis

Valuation
Currency in AUD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

New CEO Appointed to Build on Ansell’s Pandemic Success

Mark Taylor Senior Equity Analyst

Analyst Note

| Mark Taylor |

We maintain our AUD 34 fair value for narrow-moat Ansell following Neil Salmon’s appointment to succeed CEO Magnus Nicolin on Sept. 1, 2021. Salmon first joined Ansell in 2013, serving as CFO for six years before being appointed to lead the industrial global business unit in 2019. While we see little risk in the internal transition, we still expect pricing and volumes for Ansell’s products to normalise as supply eventually catches up with demand. Our long-term estimates are unchanged and consistent with management’s target range of 3% to 5% revenue growth in a normal year. Ansell is also benefitting from operating leverage and lower marketing spend due to travel restrictions, but we don’t think this is sustainable and leave our midcycle EBIT margin forecast of 15% unchanged. Shares continue to screen as overvalued at current levels.

Read Full Analysis

Company Profile

Business Description

Ansell is a leading supplier of protective gloves for use in industrial and healthcare settings, earning approximately 55% of revenue and 65% of operating profit from the healthcare segment. The company holds a large number of patents and the majority of sales come from its key branded product ranges. Ansell has a global manufacturing and distribution footprint and distributes via key partners as well as directly across more than 100 countries. In fiscal 2020, Ansell earned 42% of revenue in North America, 33% from Europe, Middle East and Africa, 11% across Asia Pacific and the remaining 7% in Latin America.

Contact
678 Victoria Street, Level 3
Richmond, VIC, 3121, Australia
T +61 392707229
Sector Healthcare
Industry Medical Instruments & Supplies
Most Recent Earnings
Fiscal Year End Jun 30, 2021
Stock Type
Employees 13,513

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.